NeuroPace, Inc. (NPCE)

Market Cap	333.63M
Revenue (ttm)	88.57M
Net Income (ttm)	-25.94M
Shares Out	33.08M
EPS (ttm)	-0.84
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,592
Open	9.95
Previous Close	9.89
Day's Range	9.86 - 10.09
52-Week Range	5.45 - 18.98
Beta	1.90
Analysts	Strong Buy
Price Target	16.67 (+65.3%)
Earnings Date	Nov 11, 2025

About NPCE

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet and patient data management system; and nSight Platform, which facil...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Apr 22, 2021
• Employees: 184
• Stock Exchange: NASDAQ
• Ticker Symbol: NPCE
• Website: https://www.neuropace.com

Financial Performance

In 2024, NeuroPace's revenue was $79.91 million, an increase of 22.14% compared to the previous year's $65.42 million. Losses were -$27.14 million, -17.64% less than in 2023.

Analyst Summary

According to 6 analysts, the average rating for NPCE stock is "Strong Buy." The 12-month stock price target is $16.67, which is an increase of 65.30% from the latest price.

Price Target

$16.67

(65.30% upside)

Analyst Consensus: Strong Buy